Identification

Summary

Iopamidol is a diagnostic imaging agent used for angiography throughout the cardiovascular system.

Brand Names
Isovue 200, Isovue 250, Isovue 300, Isovue 370, Isovue-M, Isovue-M 200
Generic Name
Iopamidol
DrugBank Accession Number
DB08947
Background

Iopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 777.0853
Monoisotopic: 776.854094955
Chemical Formula
C17H22I3N3O8
Synonyms
  • Iopamidol
  • Iopamidolum
External IDs
  • B 15 000
  • SQ 13,396
  • SQ 13396
  • SQ-13396

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AldesleukinThe risk of a hypersensitivity reaction to Iopamidol is increased when it is combined with Aldesleukin.
MetforminThe risk or severity of adverse effects can be increased when Iopamidol is combined with Metformin.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Gastromiro (Bracco) / Iopamiro (Bracco) / Iopamiron (Bayer) / Jopamiro (Bracco) / Moiopamin (Hikari Seiyaku) / Oypalomin (Fuji Yakuhin) / Solutrast (Bracco)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Iopamidol Injection USPSolution61 %IntravascularHospira Healthcare UlcNot applicableNot applicableCanada flag
Iopamidol Injection USPSolution76 %IntravascularHospira Healthcare UlcNot applicableNot applicableCanada flag
IsovueSolution612 mg/1mLIntravascularApothecary Shop Wholesale Inc.2011-07-012011-08-31US flag
Isovue 128 Inj 26%Liquid26 %IntravenousSquibb Diagnostics, Division Of Bristol Myers Squibb Canada Inc.1988-12-311998-07-30Canada flag
Isovue 128 InjectionLiquid26 %IntravenousBracco Imaging S.P.A.1998-01-082000-07-20Canada flag
Isovue 200Injection, solution408 mg/1mLIntravascularBIPSO GmbH1985-12-31Not applicableUS flag
Isovue 200Injection, solution408 mg/1mLIntravascularBracco Diagnostics Inc1985-12-31Not applicableUS flag
Isovue 200 Inj 41%Liquid41 %IntravenousSquibb Diagnostics, Division Of Bristol Myers Squibb Canada Inc.1985-12-311998-07-30Canada flag
Isovue 200 InjectionSolution41 %Intravascular; SubarachnoidBracco Imaging S.P.A.1998-01-08Not applicableCanada flag
Isovue 250Injection, solution510 mg/1mLIntravascularBIPSO GmbH1994-10-12Not applicableUS flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
PMS-iopamidolLiquid200 mg / mLIntravenous; SubarachnoidPharmascience IncNot applicableNot applicableCanada flag
PMS-iopamidolLiquid370 mg / mLIntravenousPharmascience IncNot applicableNot applicableCanada flag
PMS-iopamidolLiquid300 mg / mLIntravenousPharmascience IncNot applicableNot applicableCanada flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
PAMIRAY 370 ENJ.SOL.100 ML.Iopamidol (0.755 g/ml)SolutionIntravenousBİEM İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
PAMIRAY 370 ENJ.SOL.50 ML.Iopamidol (0.755 g/ml)SolutionIntravenousBİEM İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag

Categories

ATC Codes
V08AB04 — Iopamidol
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as iodobenzenes. These are aromatic compounds containing one or more iodine atoms attached to a benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Halobenzenes
Direct Parent
Iodobenzenes
Alternative Parents
Aryl iodides / Secondary alcohols / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids / Primary alcohols / Organopnictogen compounds / Organonitrogen compounds / Organoiodides / Hydrocarbon derivatives
Substituents
Alcohol / Aromatic homomonocyclic compound / Aryl halide / Aryl iodide / Carboximidic acid / Carboximidic acid derivative / Hydrocarbon derivative / Iodobenzene / Organic 1,3-dipolar compound / Organic nitrogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
organoiodine compound, benzenedicarboxamide, pentol (CHEBI:31711)
Affected organisms
Not Available

Chemical Identifiers

UNII
JR13W81H44
CAS number
60166-93-0
InChI Key
XQZXYNRDCRIARQ-LURJTMIESA-N
InChI
InChI=1S/C17H22I3N3O8/c1-6(28)15(29)23-14-12(19)9(16(30)21-7(2-24)3-25)11(18)10(13(14)20)17(31)22-8(4-26)5-27/h6-8,24-28H,2-5H2,1H3,(H,21,30)(H,22,31)(H,23,29)/t6-/m0/s1
IUPAC Name
N1,N3-bis(1,3-dihydroxypropan-2-yl)-5-[(2S)-2-hydroxypropanamido]-2,4,6-triiodobenzene-1,3-dicarboxamide
SMILES
C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I

References

General References
  1. Tian FX, Xu B, Lin YL, Hu CY, Zhang TY, Gao NY: Photodegradation kinetics of iopamidol by UV irradiation and enhanced formation of iodinated disinfection by-products in sequential oxidation processes. Water Res. 2014 Jul 1;58:198-208. doi: 10.1016/j.watres.2014.03.069. Epub 2014 Apr 5. [Article]
KEGG Drug
D01797
PubChem Compound
65492
PubChem Substance
310264913
ChemSpider
58940
RxNav
5966
ChEBI
31711
ChEMBL
CHEMBL1200932
ZINC
ZINC000003830947
Drugs.com
Drugs.com Drug Page
Wikipedia
Iopamidol
FDA label
Download (715 KB)
MSDS
Download (133 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingDiagnosticPercutaneous Coronary Intervention (PCI)1
4CompletedNot AvailableCIN1
4CompletedNot AvailableDrug Safety1
4CompletedNot AvailableIV Contrast Dosing1
4CompletedNot AvailableKidney Diseases1
4CompletedNot AvailablePatient Comfort and Safety1
4CompletedDiagnosticCoronary Artery Stenosis2
4CompletedDiagnosticPeripheral Arterial Occlusive Disease (PAOD)2
4CompletedDiagnosticProphylaxis of Contrast-induced nephropathy1
4CompletedDiagnosticPulmonary Embolism1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionOral; Rectal61.2 %
SolutionOral
SolutionIntra-arterial; Intravenous370 mg
SolutionIntravenous370 mg
SolutionIntra-arterial; Intravenous612.4 mg
SolutionIntra-arterial; Intra-articular; Intrathecal; Intravenous300 mg
SolutionIntravascular61 %
SolutionIntravascular76 %
Injection, solution
Injection, solutionIntravenous200 mg/mL
Injection, solutionIntravenous300 mg/mL
Injection, solutionParenteral150 MG/ML
Injection, solutionParenteral200 MG/ML
Injection, solutionParenteral300 MG/ML
Injection, solutionParenteral370 MG/ML
Solution300 mg/1ml
SolutionIntrathecal; Intravascular
InjectionIntravenous; Other6.12 g/10ml
Solution370 mg/1ml
InjectionIntravenous; Other7.55 g/10ml
SolutionParenteral408.3 mg
SolutionIntravenous612.4 mg
SolutionParenteral755.3 mg
Injection, solutionIntravenous; Parenteral61.2 %
Injection, solutionIntravenous; Parenteral75.5 %
Injection, solutionParenteral408 MG/ML
SolutionIntravascular612 mg/1mL
LiquidIntravenous26 %
Injection, solutionIntravascular408 mg/1mL
LiquidIntravenous41 %
SolutionIntravascular; Subarachnoid41 %
Injection, solutionIntravascular510 mg/1mL
Injection, solutionIntravascular612 mg/1mL
LiquidIntravenous61 %
LiquidIntravascular61 %
Injection, solutionIntravascular755 mg/1mL
LiquidIntravenous76 %
LiquidIntravascular76 %
Injection, solutionIntrathecal612 mg/1mL
Injection, solutionIntrathecal408 mg/1mL
SolutionIntrathecal408 mg/1mL
SolutionIntrathecal612 mg/1mL
Injection, solutionParenteral
InjectionParenteral
SolutionParenteral
SolutionIntravenous
LiquidIntravenous300 mg / mL
LiquidIntravenous370 mg / mL
LiquidIntravenous; Subarachnoid200 mg / mL
Injection, solutionParenteral612 mg/ml
Injection, solutionParenteral694 mg/ml
Injection, solutionParenteral755 mg/ml
Injection, solution150 mg/1ml
Injection, solution300 mg/1ml
Injection, solution370 mg/1ml
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.79 mg/mLALOGPS
logP-2.3ALOGPS
logP-0.74Chemaxon
logS-3ALOGPS
pKa (Strongest Acidic)11Chemaxon
pKa (Strongest Basic)-2.8Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count8Chemaxon
Hydrogen Donor Count8Chemaxon
Polar Surface Area188.45 Å2Chemaxon
Rotatable Bond Count10Chemaxon
Refractivity139.66 m3·mol-1Chemaxon
Polarizability54.78 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at May 27, 2014 16:50 / Updated at November 29, 2022 21:14